Financial News · Live Terminal

Page 589 of 687

Cantor Fitzgerald Adjusts Price Target on Universal Health Services to $194 From $229, Maintains Neutral Rating

Universal Health Services (UHS) has an average rating of overweight and mean price target of $228.93, according to analysts polled by FactSet.Price: $167.30, Change: $+4.76, Percent Change: +2.93%

$UHS

Wire146d ago

Autonomous Research Adjusts Blackstone PT to $119 From $129, Maintains Underperform Rating

$BX

Wire146d ago

Bernstein Adjusts Starbucks Price Target to $110 From $100, Maintains Outperform Rating

$SBUX

Wire146d ago

B. Riley Adjusts SharpLink Gaming Price Target to $11 From $10, Maintains Buy Rating

$SBET

Wire146d ago

R. Riley Adjusts Rogers Price Target to $165 From $153, Maintains Buy Rating

$ROG

Wire146d ago

B. Riley Adjusts Ribbon Communications PT to $3 From $2.90, Maintains Neutral Rating

$RBBN

Wire146d ago

Morgan Stanley Private Credit Leads $875 Million Senior Debt Financing for Bridgepointe Technologies

Morgan Stanley's (MS) Investment Management business said Wednesday that funds managed by its Private Credit platform have led an $875 million senior debt financing package for Bridgepointe Technologies.The debt financing was provided alongside the creation of a continuation vehicle led by Carlyle AlpInvest, as well as an equity investment from existing investor Charlesbank Capital Partners and Bridgepointe's management, the company said.Price: $187.79, Change: $-2.57, Percent Change: -1.35%

$MS

Wire146d ago

IMAX, HOYTS Cinemas Expand Partnership With 10 New IMAX With Laser Locations

IMAX (IMAX) said Wednesday it entered into an agreement with HOYTS Cinemas for ten new IMAX with Laser locations across Australia and New Zealand.IMAX's footprint with HOYTS will grow from four locations currently to fourteen in the coming years.At least three new locations are expected to open before the end of 2026, with additional locations planned throughout 2027 and 2028, according to the company.Price: $36.49, Change: $-0.48, Percent Change: -1.30%

$IMAX

Wire146d ago

Pfizer Says Elrexfio Significantly Improves Progression-Free Survival in People With Blood Cancer

Pfizer (PFE) said Wednesday a phase 3 trial assessing Elrexfio to treat adults with multiple myeloma showed a significant improvement in the primary endpoint of progression-free survival compared with daratumumab plus pomalidomide and dexamethasone.The candidate drug's safety and tolerability was in line with its known safety profile, the company said, adding that most people treated with the drug remained progression-free.The company said the study is ongoing to evaluate overall survival, which is a key secondary endpoint, that was not yet mature at the time of the interim analysis.Price: $26.43, Change: $-0.05, Percent Change: -0.21%

$PFE

Wire146d ago

DoubleDown Interactive Confirms Expression of Interest From Controlling Shareholder

DoubleDown Interactive (DDI) confirmed Wednesday that it has received a non-binding expression of interest from DoubleU Games, its controlling shareholder, to acquire the shares and ADSs that it does not already own for $11.25 per ADS in cash.The company has formed a special committee to review, evaluate and negotiate DoubleU Games' proposal, DoubleDown Interactive said.No decision has made regarding the proposal and there is no assurance that DoubleDown Interactive will pursue the proposal or another other strategic outcome, the company said.DoubleU Games currently has a 67.1% stake in DoubleDown Interactive.DoubleDown shares were 1.5% lower in Wednesday trading.Price: $10.78, Change: $-0.21, Percent Change: -1.91%

$DDI

Wire146d ago

Ryde Signs MoU With VinaTaxi to Explore Vietnam Opportunities

Ryde Group (RYDE) said Wednesday that it has signed a memorandum of understanding with VinaTaxi to explore strategic collaboration opportunities in Vietnam.The areas of exploration include the deployment of Ryde's platform within VinaTaxi's taxi fleet, and the development of an electric motorcycle ride-hailing ecosystem, the company said.Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE

Wire146d ago

Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program

Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS

Wire146d ago

Immunome Submits Varegacestat NDA Backed by Phase 3 Data

Immunome (IMNM) said Wednesday it has submitted a New Drug Application to the US Food and Drug Administration for varegacestat, an investigational oral treatment for adults with desmoid tumors.The filing is backed by positive Phase 3 RINGSIDE results showing significantly improved progression-free survival versus placebo, with an 84% reduction in the risk of disease progression or death and a 56% objective response rate, the company said.The company added that detailed data from the trial will be presented at the 2026 ASCO Annual Meeting.Shares of Immunome were down 2.7% in Wednesday trading.Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM

Wire146d ago

BeOne Medicines Receives US FDA Priority Review for Tevimbra Combination Therapy

BeOne Medicines' (ONC) supplemental biologics license application for Tevimbra, in combination with Ziihera and chemotherapy, was granted priority review designation by the US Food and Drug Administration, the company said Wednesday.This drug is for patients with a specific type of stomach or throat cancer that has spread or cannot be removed by surgery. It specifically targets tumors that test positive for a protein called HER2, which helps the cancer grow.Interim data from a phase 3 trial of the combination therapy supported the application, with the Tevimbra combination demonstrating statistically significant improvement in overall survival and progression-free survival, the company said.The combination therapy's safety findings in the trial were generally consistent with the component's known effects, BeOne Medicines added.Price: $296.42, Change: $-1.74, Percent Change: -0.58%

$ONC

Wire146d ago

Microsoft-Backed OpenAI Reportedly Sued by Families of Canada Mass Shooting Victims

Microsoft-backed (MSFT) OpenAI is facing multiple lawsuits alleging that the company could have prevented the suspected killer in the mass shooting in Tumbler Ridge, British Columbia from using its chatbot ChatGPT ahead of the attack, multiple media outlets reported Wednesday.According to the lawsuits, OpenAI knew that suspect Jesse Van Rootselaar was planning the attack due to the shooter's usage of ChatGPT, but made a "conscious decision not to warn authorities," a Bloomberg report said. Van Rootselaar allegedly carried out the mass shooting in February, killing eight people, and was found dead after the shooting from an apparent self-inflicted wound.The lawsuits also allege that the company wanted to avoid contacting the police each time its safety team detected a ChatGPT user planning a violent act, according to the report.OpenAI toldin an emailed statement that it had a "zero-tolerance policy" on the use of its tools to commit violence. "As we shared with Canadian officials, we have already strengthened our safeguards, including improving how ChatGPT responds to signs of distress, connecting people with local support and mental health resources, strengthening how we assess and escalate potential threats of violence, and improving detection of repeat policy violators," an OpenAI spokesperson said.Price: $425.31, Change: $-3.94, Percent Change: -0.92%

$MSFT

Wire146d ago

Citigroup Adjusts Price Target on PTC to $146 From $166, Maintains Neutral Rating

PTC (PTC) has an average rating of overweight and mean price target of $186.72, according to analysts polled by FactSet.Price: $136.13, Change: $-0.99, Percent Change: -0.72%

$PTC

Wire146d ago

B. Riley Adjusts Ares Capital Price Target to $20 From $22, Maintains Buy Rating

$ARCC

Wire146d ago

Morgan Stanley Adjusts Price Target on Centene to $50 From $45, Maintains Equalweight Rating

Centene (CNC) has an average rating of overweight and mean price target of $51.06, according to analysts polled by FactSet.Price: $52.76, Change: $+3.19, Percent Change: +6.44%

$CNC

Wire146d ago

Macquarie Cuts Price Target on Sportradar Group to $24 From $30, Keeps Outperform Rating

Sportradar Group (SRAD) has an average rating of buy and mean price target of $22.88 according to analysts polled by FactSet.Price: $12.47, Change: $+0.12, Percent Change: +0.97%

$SRAD

Wire146d ago

TransMedics Group Agrees to Invest in PAD Aviation for European Transplant Logistics Network

TransMedics Group (TMDX) said Wednesday it agreed to invest in Germany-based private aviation operator PAD Aviation to establish a dedicated air and ground logistics network for organ transplants in Europe.The project will support the firm's OCS perfusion platform and clinical services to help expand access to donor organs and increase transplant volumes across the European Union, the company said.Management anticipates closing the deal later in 2026, subject to standard regulatory approvals and closing conditions, TransMedics said.Shares of the company were down 1.9% in Wednesday trading.Price: $99.63, Change: $-1.63, Percent Change: -1.61%

$TMDX

Showing 11761-11780 of 13724